Early-onset Alzheimer's advances quickly -- and the rapid decline is devastating. That's why researchers are racing to find ...

Now, two independent studies have honed in on inflammatory microglia as a potential therapeutic strategy. In mice, induction of T regulatory (T reg) cells or supplementation with a metabolic ...

For cognitively healthy people who carried an autosomal dominant AD mutation, eight years of treatment with gantenerumab halved the odds of developing symptoms. A preliminary analysis was presented at ...

The anti-amyloid therapy gantenerumab lowered the chances for developing Alzheimer’s-related dementia in people at high risk for the disease, according to a small study conducted by the Knight ...

Get Instant Summarized Text (Gist) A long-term trial of gantenerumab for dominantly inherited Alzheimer's disease was halted due to safety concerns, including brain bleeding and swelling. Although ...

In late-stage clinical trials involving more than 1,800 people with early Alzheimer’s disease, one of these drugs, gantenerumab, slowed the progression of symptoms compared with a placebo, ...

"I am highly optimistic now, as this could be the first clinical evidence of what will become preventions for people at risk for Alzheimer's disease." HealthDay News — For individuals with ...

For 22 of the participants who received a drug called gantenerumab for eight years, their risk of developing symptoms was cut in half — from 100% to 50% — the researchers reported.